Martinsried/Munich, April 3, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell ...
Medigene has agreed to expand its nearly two-year-old, up-to-$1 billion-plus cancer immunotherapy collaboration with bluebird bio, saying today that the expansion could generate up to $509 ...
Martinsried/Munich, October 1, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) and three private investors have founded Immunocore Ltd, which will focus on the technology platform for monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback